All In Biotech

Drug Trial Radar · NCT01962415

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation

Last checked: Nov 20, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Feb 4, 2014

Primary completion

Nov 2026

Study completion Nov 2027

Sponsor

Lead sponsor
Paul SzabolcsAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 14, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 months, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). After transplant, subjects will be followed for late effects and for ongoing graft success.

Conditions

  • Primary Immunodeficiency (PID)
  • Congenital Bone Marrow Failure Syndromes
  • Inherited Metabolic Disorders (IMD)
  • Hereditary Anemias
  • Inflammatory Conditions
  • Systemic Juvenile Idiopathic Arthritis (sJIA)
  • Juvenile Rheumatoid Arthritis (JRA)

Interventions

  • HydroxyureaDrug

    Oral administration

  • AlemtuzumabDrug

    Intravenous (IV) administration.

  • FludarabineDrug

    IV administration

  • MelphalanDrug

    IV administration

  • ThiotepaDrug

    IV administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Post-transplant treatment-related mortality (TRM)Time frame: 1 year post-transplant
  2. Neurodevelopmental milestonesTime frame: 1 year post-transplant
  3. Immune ReconstitutionTime frame: 1 year post-transplant
  4. Severe opportunistic infectionsTime frame: 1 year post-transplant
  5. GVHD occurrenceTime frame: 1 year post-transplant

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.